The Conversation (0)
Insulet Corporation (NASDAQ:PODD), which has a tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc. (NASDAQ:AMGN) for a 5-year commercial agreement to supply Amgen with a delivery device designed around the delivery needs of biotechnology medicines.
Insulet Corporation (NASDAQ:PODD), which has a tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced an agreement with Amgen Inc. (NASDAQ:AMGN) for a 5-year commercial agreement to supply Amgen with a delivery device designed around the delivery needs of biotechnology medicines.
As quoted in the market news:
“We are thrilled to advance our collaboration with Amgen to supply this version of our technology,” said Duane DeSisto, President and Chief Executive Officer of Insulet.
DeSisto added that “Insulet’s current device, the OmniPod®, is a unique drug delivery platform that provides the ability to vary rate at which medication is infused. With over 25 million OmniPods produced, our innovative product is the undisputed global leader in patch pump technology and provides a patient-friendly and cost effective drug delivery alternative.”
Read the full news release by Insulet Corporation (NASDAQ:PODD)